Kiniksa Pharmaceuticals, Ltd.
General ticker "KNSA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.0B (TTM average)
Kiniksa Pharmaceuticals, Ltd. follows the US Stock Market performance with the rate: 53.3%.
Estimated limits based on current volatility of 2.9%: low 37.63$, high 39.95$
Factors to consider:
- Total employees count: 315 (+6.1%) as of 2024
- Top business risk factors: Product commercialization failure, Regulatory and compliance, Product development delays, Expansion risks, Financing risks
- Current price 15.2% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [18.05$, 31.85$]
- 2025-12-31 to 2026-12-31 estimated range: [19.60$, 34.20$]
Financial Metrics affecting the KNSA estimates:
- Negative: with PPE of -32.9 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Inventory ratio change, % of -4.37 <= -0.76
- Positive: Shareholder equity ratio, % of 75.52 > 64.17
- Negative: negative Industry operating cash flow (median)
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term KNSA quotes
Long-term KNSA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $220.18MM | $270.26MM | $423.24MM |
| Operating Expenses | $210.41MM | $295.45MM | $468.86MM |
| Operating Income | $9.77MM | $-25.20MM | $-45.62MM |
| Non-Operating Income | $1.25MM | $8.54MM | $9.46MM |
| R&D Expense | $65.49MM | $76.10MM | $111.62MM |
| Income(Loss) | $11.03MM | $-16.65MM | $-36.15MM |
| Taxes | $-172.34MM | $-30.74MM | $7.04MM |
| Profit(Loss)* | $183.36MM | $14.08MM | $-43.19MM |
| Stockholders Equity | $396.15MM | $438.84MM | $438.44MM |
| Inventory | $21.60MM | $31.12MM | $26.36MM |
| Assets | $459.67MM | $526.32MM | $580.55MM |
| Operating Cash Flow | $5.81MM | $13.30MM | $25.69MM |
| Capital expenditure | $0.10MM | $0.13MM | $0.28MM |
| Investing Cash Flow | $-8.08MM | $-29.56MM | $37.67MM |
| Financing Cash Flow | $2.52MM | $1.50MM | $12.27MM |
| Earnings Per Share** | $2.64 | $0.20 | $-0.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.